RHHBF - Roche to acquire Telavant for $7.1B adds new bowel disease therapy to pipeline
2023-10-23 03:10:38 ET
More on Roche, Roivant Sciences
- Skin In The Game: Behind Roivant's Significant Rise
- Be Patient, Roche Is A Clear Buy At This Price
- Roche: Positive Readouts From Pipeline
- Roche: 2023 Should Mark The Bottom
- Roche slips after in-line Q3 sales
For further details see:
Roche to acquire Telavant for $7.1B, adds new bowel disease therapy to pipeline